Cindy Leissinger
Overview
Explore the profile of Cindy Leissinger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
1108
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Hemophilia A: Strategies for Improving Long-Term Holistic Management, Adherence, and Quality of Life
Escobar M, Leissinger C, Young G
J Adv Pract Oncol
. 2022 Jun;
13(Suppl 3):7-20.
PMID: 35769336
Hemophilia A is a rare inherited bleeding disorder characterized by a deficiency in factor VIII. The evolution of currently approved prophylaxis therapy in hemophilia A will be reviewed, including the...
3.
Escobar M, Mancuso M, Hermans C, Leissinger C, Seifert W, Li Y, et al.
J Clin Med
. 2022 Feb;
11(4).
PMID: 35207344
Hemophilia B is a bleeding disorder caused by a deficiency of coagulation factor IX (FIX). Treatment with FIX replacement products can increase FIX activity levels to minimize or prevent bleeding...
4.
Escobar M, Castaman G, Boix S, Callaghan M, Moerloose P, Ducore J, et al.
Haemophilia
. 2021 Oct;
27(6):921-931.
PMID: 34636112
Introduction: Haemophilia patients with inhibitors often require a bypassing agent (BPA) for bleeding episode management. Eptacog beta (EB) is a new FDA-approved recombinant activated human factor VII BPA for the...
5.
Escobar M, Luck J, Averianov Y, Ducore J, Lopez Fernandez M, Giermasz A, et al.
Haemophilia
. 2021 Oct;
27(6):911-920.
PMID: 34614267
Introduction: Surgical procedures in persons with haemophilia A or B with inhibitors (PwHABI) require the use of bypassing agents (BPA) and carry a high risk of complications. Historically, only two...
6.
Doshi B, Rana J, Castaman G, Shaheen M, Kaczmarek R, Butterfield J, et al.
J Clin Invest
. 2021 Mar;
131(8).
PMID: 33651716
Inhibitors of factor VIII (FVIII) remain the most challenging complication of FVIII protein replacement therapy in hemophilia A (HA). Understanding the mechanisms that guide FVIII-specific B cell development could help...
7.
Janbain M, Enjolras N, Bordet J, Bolbos R, Brevet M, Leissinger C, et al.
J Thromb Haemost
. 2019 Nov;
18(3):584-592.
PMID: 31782901
Background: Hemophilia is characterized by a compromised hemostatic response with delayed development of a clot and the formation of clots that are vulnerable to fibrinolysis. We proposed to study, in...
8.
Warren B, Jacobson L, Kempton C, Buchanan G, Recht M, Brown D, et al.
Haemophilia
. 2019 May;
25(5):867-875.
PMID: 31115111
Introduction: The Joint Outcome Study (JOS) demonstrated that previously untreated children with severe haemophilia A treated with prophylactic factor VIII (FVIII) concentrate had superior joint outcomes at age 6 years...
9.
Aledort L, Carpenter S, Cuker A, Kulkarni R, Recht M, Young G, et al.
Haemophilia
. 2019 Mar;
25(3):e183-e185.
PMID: 30866124
No abstract available.
10.
Sood S, Cheng D, Ragni M, Kessler C, Quon D, Shapiro A, et al.
Blood Adv
. 2018 Jun;
2(11):1325-1333.
PMID: 29895623
Men with hemophilia were initially thought to be protected from cardiovascular disease (CVD), but it is now clear that atherothrombotic events occur. The primary objective of the CVD in Hemophilia...